Can Statins Reduce Perioperative Morbidity and Mortality in Patients Undergoing Non-Cardiac Vascular Surgery?

European Journal of Vascular and Endovascular Surgery

Volumn 32, Issue 3, 2006, Pages 286-293

  Paraskevas, K I ^a   Liapis, C D ^a   Hamilton, G ^b   Mikhailidis, D P ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Academic Department of Surgery

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular disease; Perioperative mortality; Statins; Vascular surgery

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CERIVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL AORTA ANEURYSM; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DRUG SAFETY; DRUG USE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LEG REVASCULARIZATION; MEDLINE; MORBIDITY; MORTALITY; MYOPATHY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; VASCULAR SURGERY;

ADRENERGIC BETA-ANTAGONISTS; AORTIC ANEURYSM, ABDOMINAL; ARTERIAL OCCLUSIVE DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METOPROLOL; MORBIDITY; MULTIVARIATE ANALYSIS; VASCULAR SURGICAL PROCEDURES;

EID: 33747052530     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2006.03.009     Document Type: Review

References (91)

1. Badner N.H., Knill R.L., Brown J.E., Novick T.V., and Gelb A.W. Myocardial infarction after noncardiac surgery. Anesthesiology 88 (1998) 572-578
2. Mangano D.T. Perioperative cardiac morbidity. Anesthesiology 72 (1990) 153-184
3. Passman R.S., Gingold D.S., Amar D., et al. Prediction rule for atrial fibrillation after major noncardiac thoracic surgery. Ann Thorac Surg 79 (2005) 1698-1703
4. Christians K.K., Wu B., Quebbeman E.J., and Brasel K.J. Postoperative atrial fibrillation in noncardiothoracic surgical patients. Am J Surg 182 (2001) 713-715
5. Amar D., Zhang H., and Roistacher N. The incidence and outcome of ventricular arrhythmias after noncardiac thoracic surgery. Anesth Analg 95 (2002) 537-543
6. Fleischmann K.E., Goldman L., Young B., and Lee T.H. Association between cardiac and noncardiac complications in patients undergoing noncardiac surgery: outcomes and effects on length of stay. Am J Med 115 (2003) 515-520
7. Poldermans D., Boersma E., Bax J.J., et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 341 (1999) 1789-1794
8. Mangano D.T., Layug E.L., Wallace A., and Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 335 (1996) 1713-1720
9. Farkouh M.E., Rihal C.S., Gersh B.J., et al. Influence of coronary heart disease on morbidity and mortality after lower extremity revascularization surgery: a population-based study in Olmsted County, Minnesota (1970-1987). J Am Coll Cardiol 24 (1994) 1290-1296
10. Mangano D.T., Browner W.S., Hollenberg M., London M.J., and Tateo I.M. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med 323 (1990) 1781-1788
11. Lee T.H., Marcantonio E.R., Mangione C., et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 100 (1999) 1043-1049
12. Boersma E., Kertai M.D., Schouten O., et al. Perioperative cardiovascular mortality in noncardiac surgery: validation of the Lee cardiac index. Am J Med 118 (2005) 1134-1141
13. Fleisher L.A., and Eagle K.A. Clinical practice. Lowering cardiac risk in noncardiac surgery. N Engl J Med 345 (2001) 1677-1682
14. Grimm Jr. R.H., Tillinghast S., Daniels K., et al. Unrecognized myocardial infaction: experience in the Multiple Risk Factor Intervention Trial (MRFIT). Circulation 75 (1987) II6-II8
15. Sigurdsson E., Thorgeirsson G., Sigvaldason H., and Sigfusson N. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med 122 (1995) 96-102
16. Sheifer S.E., Gersh B.J., Yanez III N.D., Ades P.A., Burke G.L., and Manolio T.A. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol 35 (2000) 119-126
17. Schouten O., van Waning V.H., Kertai M.D., et al. Perioperative and long-term cardiovascular outcomes in patients undergoing endovascular treatment compared with open vascular surgery for abdominal aortic aneurysm or iliaco-femoro-popliteal bypass. Am J Cardiol 96 (2005) 861-866
18. Lindenauer P.K., Fitzgerald J., Hoople N., and Benjamin E.M. The potential preventability of postoperative myocardial infarction: underuse of perioperative β-adrenergic blockade. Arch Intern Med 164 (2004) 762-766
19. Nettleman M.D., Banitt L., Barry W., Awan I., and Gordon E.E.I. Predictors of survival and the role of gender in postoperative myocardial infarction. Am J Med 103 (1997) 357-362
20. Poldermans D., Boersma E., Bax J.J., et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 22 (2001) 1353-1358
21. Eagle K.A., Berger P.B., Calkins H., et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiac Evaluation for Noncardiac Surgery). J Am Coll Cardiol 39 (2002) 542-553
22. Grayburn P.A., and Hillis L.D. Cardiac events in patients undergoing noncardiac surgery: shifting the paradigm from noninvasive risk stratification to therapy. Ann Intern Med 138 (2003) 506-511
23. Wallace A., Layug B., Tateo I., et al. Prophylactic atenolol reduces postoperative myocardial ischemia. Anesthesiology 88 (1998) 7-17
24. Brady A.R., Gibbs J.S., Greenhalgh R.M., Powell J.T., Sydes M.R., and POBBLE trial investigators. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. J Vasc Surg 41 (2005) 602-609
25. Kertai M.D., Boersma E., Bax J.J., et al. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE) Study Group. Optimizing long-term cardiac management after major vascular surgery: Role of beta-blocker therapy, clinical characteristics, and dobutamine stress echocardiography to optimize long-term cardiac management after major vascular surgery. Arch Intern Med 163 (2003) 2230-2235
26. Wijeysundera D.N., and Beattie W.S. Calcium channel blockers for reducing cardiac morbidity and mortality after noncardiac surgery: a meta-analysis. Anest Analg 97 (2003) 634-641
27. Oliver M.F., Goldman L., Julian D.G., and Holme I. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology 91 (1999) 951-961
28. Wallace A.W., Galindez D., Salahieh A., et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology 101 (2004) 284-293
29. Nishina K., Mikawa K., Uesugi T., et al. Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature. Anesthesiology 96 (2002) 323-329
30. Robless P., Mikhailidis D.P., and Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral arterial disease. Br J Surg 88 (2001) 787-800
31. Devereax P.J., Goldman L., Yusuf S., Gilbert K., Leslie K., and Guyatt G.H. Surveillance and prevention of major perioperative ischemic events in patients undergoing noncardiac injury: a review. CMAJ 173 (2005) 779-788
32. Henke P.K., Blackburn S., Proctor M.C., et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 39 (2004) 357-365
33. Dawood M.M., Gutpa D.K., Southern J., Walia A., Atkinson J.B., and Eagle K.A. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol 57 (1996) 37-44
34. Morishita R., Tomita N., and Ogihara T. HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque. Curr Drug Targets 3 (2002) 379-385
35. Ikeda U., and Shimada K. Pleiotropic effects of statins on the vascular tissue. Curr Drug Targets Cardiovasc Haematol Disord 1 (2001) 51-58
36. Luo J.D., and Chen A.F. Perspectives on the cardioprotective effects of statins. Curr Med Chem 10 (2003) 1593-1601
37. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
38. van Haelst P.L., van Doormaal J.J., May J.F., Gans R.O., Crijns H.J., and Coven Tervaert J.W. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur J Intern Med 12 (2001) 503-509
39. Laufs U., and Liao J.K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 10 (2000) 143-148
40. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
41. Laufs U., La Fata V., Plutzky J., et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
42. Albert M.A., Danielson E., Rifai N., Ridker P.M., and PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomised trial and cohort study. JAMA 286 (2001) 64-70
43. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98 (1998) 839-844
44. Milionis H.J., Elisaf M.S., and Mikhailidis D.P. The effect of lipid-regulating therapy on haemostatic parameters. Curr Pharm Design 9 (2003) 2425-2443
45. Biccard B.M., Sear J.W., and Foex P. Statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease. Anaesthesia 60 (2005) 1106-1114
46. Biccard B.M., Sear J.W., and Foex P. The pharmaco-economics of peri-operative statin therapy. Anaesthesia 60 (2005) 1059-1063
47. Poldermans D., Bax J.J., Kertai M.D., et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 107 (2003) 1848-1851
48. Durazzo A.E., Machado F.S., Ikeoka D.T., et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 39 (2004) 967-976
49. Lindenauer P.K., Pekow P., Wang K., Gutierrez B., and Benjamin E.M. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 291 (2004) 2092-2099
50. O'neil-Callahan K., Katsimaglis G., Tepper M.R., et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. J Am Coll Cardiol 45 (2005) 336-342
51. McGirt M.J., Perler B.A., Brooke B.S., et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 42 (2005) 829-836
52. Kennedy J., Quan H., Buchan A.M., Ghali W.A., and Feasby T.E. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 36 (2005) 2072-2076
53. Kertai M.D., Boersma E., Westerhout C.M., et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 116 (2004) 96-103
54. Krupski W.C., Layug E.L., Reilly L.M., Rapp J.H., and Mangano D.T. Comparison of cardiac morbidity rates between aortic and infrainguinal operations: two-year follow-up. Study of Perioperative Ischemia Research Group. J Vasc Surg 18 (1993) 609-615
55. United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 346 (2002) 1445-1452
56. Boersma E., Poldermans D., Bax J.J., et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 285 (2001) 1865-1873
57. Parker Ward R., Leeper N.J., Kirkpatrick J.N., Lang R.M., Sorrentino M.J., and Williams K.A. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 104 (2005) 264-268
58. Abbruzzese T.A., Havens J., Belkin M., et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 39 (2004) 1178-1185
59. Kertai M.D., Boersma E., Westerhout C.M., et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 28 (2004) 343-352
60. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al., GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 18 (2004) 781-788
61. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 16 (2005) 65-71
62. Schouten O., Poldermans D., Visser L., et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study. Am Heart J 148 (2004) 1047-1052
63. McDermott M.M., Criqui M.H., Liu K., et al. Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial artery pressures, and association with leg functioning in peripheral arterial disease. J Vasc Surg 32 (2000) 1164-1171
64. McDermott M.M., Greenland P., Liu K., et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 136 (2002) 873-883
65. Mondillo S., Ballo P., Barbati R., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114 (2003) 359-364
66. McDermott M.M., Guralnik J.M., Greenland P., et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 107 (2003) 757-761
67. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
68. Daskalopoulou S.S., Daskalopoulos M.E., Liapis C.D., and Mikhailidis D.P. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 12 (2005) 443-452
69. Youssef F., Seifalian A.M., Jagroop A., et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 23 (2002) 358-364
70. Athyros V.G., Elisaf M., Papageorgiou A.A., et al., GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 43 (2004) 589-599
71. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. The effects of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. J Clin Pathol 57 (2004) 728-734
72. Elisaf M., and Mikhailidis D.P. Statins and renal function. Angiology 53 (2002) 493-502
73. Alnaeb M.E., Youssef F., Mikhailidis D.P., and Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology 57 (2006) 65-71
74. Kertai M.D., Boersma E., Bax J.J., van der Meiracker A.H., van Urk H., Roelandt J.R., et al. Comparison between serum creatinine clearance for the prediction of postoperative mortality in patients undergoing major vascular surgery. Clin Nephrol 59 (2003) 17-23
75. Vahl A.C., and Reekers J.A. The guideline 'Diagnosis and treatment of peripheral artery disease of the lower extremities' of The Netherlands Surgical Society. Ned Tijdschr Geneeskd 149 (2005) 1670-1674
76. Schouten O., Kertai M.D., Bax J.J., et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 95 (2005) 658-660
77. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
78. Bellosta S., Paoletti R., and Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109 23 Suppl. I (2004) III50-III57
79. Rosenson R.S. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408-416
80. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106 (2002) 1024-1028
81. Moosmann B., and Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 363 (2004) 892-894
82. Mikhailidis D.P., Wierzbicki A.S., Daskalopoulou S.S., et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 21 (2005) 959-969
83. Grundy S.M., Cleeman J.I., Merz C.N., et al. National heart, lung, and blood institute; American college of cardiology foundation; American heart foundation. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
84. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European Society of Cardiology. American Heart Association. American College of Cardiology. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 173 (2004) 381-391
85. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., Di Sciascio G., and ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 110 (2004) 674-678
86. Lazar H.L. Role of statin therapy in the coronary bypass surgery. Ann Thorac Surg 78 (2004) 730-740
87. Cosio F.G., Pesavento T.E., Pelletier R.P., et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis 32 (2002) 713-716
88. Lentine K.L., and Brennan D.C. Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrol Dial Transplant 19 (2004) 2378-2386
89. Wu A.H., Ballantyne C.M., Short B.C., et al. Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Am J Cardiol 95 (2005) 367-372
90. Wenke K., Meiser B., Thiery J., and Reichart B. Impact of simvastatin therapy after heart transplantation: an 11-year prospective evaluation. Herz 30 (2005) 431-432
91. Johnson B.A., Iacono A.T., Zeevi A., McCurry K.R., and Duncan S.R. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 167 (2003) 1271-1278